224 related articles for article (PubMed ID: 12527888)
1. Altered expression of the RON receptor tyrosine kinase in primary human colorectal adenocarcinomas: generation of different splicing RON variants and their oncogenic potential.
Zhou YQ; He C; Chen YQ; Wang D; Wang MH
Oncogene; 2003 Jan; 22(2):186-97. PubMed ID: 12527888
[TBL] [Abstract][Full Text] [Related]
2. Overexpression and activation of the RON receptor tyrosine kinase in a panel of human colorectal carcinoma cell lines.
Chen YQ; Zhou YQ; Angeloni D; Kurtz AL; Qiang XZ; Wang MH
Exp Cell Res; 2000 Nov; 261(1):229-38. PubMed ID: 11082293
[TBL] [Abstract][Full Text] [Related]
3. Blocking tumorigenic activities of colorectal cancer cells by a splicing RON receptor variant defective in the tyrosine kinase domain.
Wang MH; Lao WF; Wang D; Luo YL; Yao HP
Cancer Biol Ther; 2007 Jul; 6(7):1121-9. PubMed ID: 17611409
[TBL] [Abstract][Full Text] [Related]
4. Point mutations and overexpression of Ron induce transformation, tumor formation, and metastasis.
Peace BE; Hughes MJ; Degen SJ; Waltz SE
Oncogene; 2001 Sep; 20(43):6142-51. PubMed ID: 11593422
[TBL] [Abstract][Full Text] [Related]
5. A novel variant of the RON receptor tyrosine kinase derived from colorectal carcinoma cells which lacks tyrosine phosphorylation but induces cell migration.
Wang D; Lao WF; Kuang YY; Geng SM; Mo LJ; He C
Exp Cell Res; 2012 Dec; 318(20):2548-58. PubMed ID: 22975341
[TBL] [Abstract][Full Text] [Related]
6. RNA-mediated gene silencing of the RON receptor tyrosine kinase alters oncogenic phenotypes of human colorectal carcinoma cells.
Xu XM; Wang D; Shen Q; Chen YQ; Wang MH
Oncogene; 2004 Nov; 23(52):8464-74. PubMed ID: 15378025
[TBL] [Abstract][Full Text] [Related]
7. Identification of a novel splicing product of the RON receptor tyrosine kinase in human colorectal carcinoma cells.
Wang MH; Kurtz AL; Chen Y
Carcinogenesis; 2000 Aug; 21(8):1507-12. PubMed ID: 10910951
[TBL] [Abstract][Full Text] [Related]
8. Oncogenesis of RON receptor tyrosine kinase: a molecular target for malignant epithelial cancers.
Wang MH; Yao HP; Zhou YQ
Acta Pharmacol Sin; 2006 Jun; 27(6):641-50. PubMed ID: 16723080
[TBL] [Abstract][Full Text] [Related]
9. RON alternative splicing regulation in primary ovarian cancer.
Mayer S; Hirschfeld M; Jaeger M; Pies S; Iborra S; Erbes T; Stickeler E
Oncol Rep; 2015 Jul; 34(1):423-30. PubMed ID: 25997828
[TBL] [Abstract][Full Text] [Related]
10. MET(PRC) mutations in the Ron receptor result in upregulation of tyrosine kinase activity and acquisition of oncogenic potential.
Williams TA; Longati P; Pugliese L; Gual P; Bardelli A; Michieli P
J Cell Physiol; 1999 Dec; 181(3):507-14. PubMed ID: 10528237
[TBL] [Abstract][Full Text] [Related]
11. Agonistic monoclonal antibodies potentiate tumorigenic and invasive activities of splicing variant of the RON receptor tyrosine kinase.
Yao HP; Luo YL; Feng L; Cheng LF; Lu Y; Li W; Wang MH
Cancer Biol Ther; 2006 Sep; 5(9):1179-86. PubMed ID: 16880737
[TBL] [Abstract][Full Text] [Related]
12. Point mutations in the tyrosine kinase domain release the oncogenic and metastatic potential of the Ron receptor.
Santoro MM; Penengo L; Minetto M; Orecchia S; Cilli M; Gaudino G
Oncogene; 1998 Aug; 17(6):741-9. PubMed ID: 9715276
[TBL] [Abstract][Full Text] [Related]
13. Mechanisms of cytoplasmic {beta}-catenin accumulation and its involvement in tumorigenic activities mediated by oncogenic splicing variant of the receptor originated from Nantes tyrosine kinase.
Xu XM; Zhou YQ; Wang MH
J Biol Chem; 2005 Jul; 280(26):25087-94. PubMed ID: 15878878
[TBL] [Abstract][Full Text] [Related]
14. Targeted expression of the receptor tyrosine kinase RON in distal lung epithelial cells results in multiple tumor formation: oncogenic potential of RON in vivo.
Chen YQ; Zhou YQ; Fisher JH; Wang MH
Oncogene; 2002 Sep; 21(41):6382-6. PubMed ID: 12214279
[TBL] [Abstract][Full Text] [Related]
15. Oncogenic and invasive potentials of human macrophage-stimulating protein receptor, the RON receptor tyrosine kinase.
Wang MH; Wang D; Chen YQ
Carcinogenesis; 2003 Aug; 24(8):1291-300. PubMed ID: 12807733
[TBL] [Abstract][Full Text] [Related]
16. Alterations in a defined extracellular region of the RON receptor tyrosine kinase promote RON-mediated motile and invasive phenotypes in epithelial cells.
Zhang K; Zhou YQ; Yao HP; Wang MH
Int J Oncol; 2010 Jan; 36(1):255-64. PubMed ID: 19956854
[TBL] [Abstract][Full Text] [Related]
17. Multiple variants of the RON receptor tyrosine kinase: biochemical properties, tumorigenic activities, and potential drug targets.
Lu Y; Yao HP; Wang MH
Cancer Lett; 2007 Nov; 257(2):157-64. PubMed ID: 17889431
[TBL] [Abstract][Full Text] [Related]
18. Multiple pulmonary adenomas in the lung of transgenic mice overexpressing the RON receptor tyrosine kinase. Recepteur d'origine nantais.
Chen YQ; Zhou YQ; Fu LH; Wang D; Wang MH
Carcinogenesis; 2002 Nov; 23(11):1811-9. PubMed ID: 12419829
[TBL] [Abstract][Full Text] [Related]
19. A novel protein isoform of the RON tyrosine kinase receptor transforms human pancreatic duct epithelial cells.
Chakedis J; French R; Babicky M; Jaquish D; Howard H; Mose E; Lam R; Holman P; Miyamoto J; Walterscheid Z; Lowy AM
Oncogene; 2016 Jun; 35(25):3249-59. PubMed ID: 26477314
[TBL] [Abstract][Full Text] [Related]
20. RON and RONΔ160 promote gastric cancer cell proliferation, migration, and adaption to hypoxia via interaction with β-catenin.
Zhou D; Huang L; Zhou Y; Wei T; Yang L; Li C
Aging (Albany NY); 2019 May; 11(9):2735-2748. PubMed ID: 31085796
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
